Drug Price Trends for NDC 75826-0118

Average Pharmacy Cost for 75826-0118

Drug Name	NDC	Price/Unit ($)	Unit	Date

Best Wholesale Price for NDC 75826-0118

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type

Market Analysis and Price Projections for NDC 75826-0118

Last updated: February 14, 2026

Product Overview

NDC 75826-0118 corresponds to Samsca (tolvaptan), a vasopressin receptor antagonist approved for the treatment of hyponatremia associated with syndrome of inappropriate antidiuretic hormone secretion (SIADH) and congestive heart failure (CHF). Approved by the FDA in 2013, Samsca addresses a niche market with limited competition, mainly due to its specific indication and management guidelines.

---

Market Size and Segmentation

1. Prevalence Rates:

   • Hyponatremia Cases: Approximately 3-4% of hospitalized patients experience hyponatremia. Among these, 50-60% are related to SIADH.

   • Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH): An estimated 2 million cases annually in the US, primarily in hospitalized or chronic care settings.

   • Congestive Heart Failure (CHF): The US sees about 6.2 million diagnosed with CHF, with an estimated 10-15% developing hyponatremia.

2. Treatment Penetration:

   • Samsca’s use remains limited to specific cases under monitoring, with current prescription rates estimated at 20,000–25,000 annually in the US.

3. Market Players:

   • Currently, Samsca holds a dominant position for hyponatremia due to SIADH.

   • Off-label use is minimal; no direct biosimilars or generics are present as of 2023.

---

Regulatory and Reimbursement Environment

• FDA Approval: Specific indications restrict use to hyponatremia and CHF management.
• Pricing and Reimbursement: Commercial list price in the US approximates $560 per 15 mg tablet, with actual reimbursed prices often lower depending on insurance coverage.
• Market Access: Reimbursement policies are restrictive; prescriptions require careful patient selection due to risks like hepatotoxicity and overly rapid correction of sodium.

---

Competitive Landscape

• Existing Options: Limited, mostly fluid restriction and hypertonic saline, which are less targeted.
• Pipeline: No major competitors with similar approved indications. Some investigational drugs target hyponatremia, but none are in late-stage development or approved.

---

Price Projections

1. Current Price Point:

   • Average wholesale price (AWP) for Samsca remains at approximately $560 per tablet.
   • Monthly treatment (30 days): ~$16,800 at current dosing (1-15 mg daily).

2. Forecast 2023-2028:

   • No significant price reductions expected due to lack of generic competition.

   • Slight discounts via contract pricing and patient assistance programs could lower actual costs by 10-15%.

   • Market Growth Drivers:

     • Increased awareness among clinicians.
     • Expansion of use in off-label but clinically supported conditions.
     • Growing prevalence of hyponatremia in HF patients.

3. Potential Price Trends:

   • Slow Decline: Due to patent protections until at least 2027, prices may gradually decline at 2-3% annually, in line with inflation and market dynamics.

   • Post-Patent Scenario: If a biosimilar or generic enters by 2028-2030, prices could fall by 30-50% within 1-2 years, assuming market entry and uptake.

---

Revenue Projections

Year	Prescriptions (Estimate)	Revenue (US, USD)	Notes
2023	25,000	$420 million	Based on $16,800 per patient monthly
2024	27,000	$456 million	Slight increase in prescription volume
2025	30,000	$510 million	Growing clinician awareness
2026	33,000	$561 million	Market penetration deepens
2027	36,000	$612 million	Near patent expiry

---

Key Takeaways

• Samsca (tolvaptan) faces a large unmet need but limited competition.
• Current US list price is roughly $560 per tablet with stable projections through 2027.
• Prescription volume is expected to grow modestly, driven by increasing prevalence and clinical adoption.
• Patent expiration or approval of biosimilars could reduce prices significantly after 2027-2028.
• Reimbursement constraints influence penetration, but demand remains steady for approved indications.

---

FAQs

1. How will patent expiration affect Samsca’s pricing?

   Patent expiry around 2027 could lead to biosimilar entry, potentially reducing prices by up to 50% within 1-2 years.

2. Are there any upcoming competitors?

   No approved drugs directly compete with Samsca for hyponatremia; pipeline drugs are limited and in early development stages.

3. What factors influence Samsca’s market growth?

   Disease prevalence, clinician familiarity, reimbursement policies, and safety profile.

4. How does off-label use impact the market?

   Minor, as off-label prescriptions are not covered by reimbursement policies and lack formal approval, constraining market expansion.

5. What are risk factors for Samsca’s market future?

   Safety concerns such as hepatotoxicity, rapid sodium correction risks, and regulatory restrictions.

---

References

[1] FDA. Samsca (tolvaptan) Prescribing Information. 2013.

[2] MarketWatch. Hyponatremia treatment market forecast report, 2022.

[3] CDC. Hyponatremia prevalence and clinical data, 2021.

[4] EvaluatePharma. 2022 Global Market Outlook for Specialty Drugs.

[5] IQVIA. Prescription Trends for Hyponatremia Drugs, 2022.

---

Note: Data and forecasts are estimates based on current market conditions and publicly available sources. Actual market dynamics can vary.